Resverlogix Announces Voting Results from the 2022 Meeting of Shareholders
June 21 2022 - 10:30PM
Resverlogix Corp. (“Resverlogix”, or the "Corporation") (TSX:RVX)
today held its Annual Meeting of Shareholders (the “Meeting”) in
Calgary, Alberta.
During business proceedings at the Meeting,
shareholders elected five (5) Board members until the next annual
meeting. The voting results of shares represented at the Meeting
for individual directors were as follows:
|
Votes For |
Votes Withheld |
Percent For |
Percent Withheld |
Donald J. McCaffrey |
125,007,142 |
7,326,179 |
94.46% |
5.54% |
Shawn Lu |
126,119,539 |
6,213,782 |
95.30% |
4.70% |
Kelly McNeill |
125,955,508 |
6,377,813 |
95.18% |
4.82% |
Siu Lun (Dicky) To |
127,354,197 |
4,979,124 |
96.24% |
3.76% |
Kenneth Zuerblis |
127,166,543 |
5,166,778 |
96.10% |
3.90% |
Resverlogix shareholders approved all
resolutions outlined in the Notice of Meeting and Management
Information Circular dated May 11, 2022 (the “Information
Circular”). The Information Circular is available on SEDAR at
www.sedar.com, and on the Resverlogix website at
www.resverlogix.com.
A webcast archive of the executive presentation
portion of the Meeting will be available HERE.
About Resverlogix
Founded in 2001, Resverlogix is a Calgary based
late-stage biotechnology company and the world leader in
epigenetics, or gene regulation, with the goal of developing
first-in-class therapies for the benefit of patients with chronic
disease.
Resverlogix is developing a new class of
epigenetic therapies designed to regulate the expression of
disease-causing genes. We aim to improve patients’ lives by
restoring biological functions – altered by serious illnesses such
as cardiovascular disease – back to a healthier state.
The Company’s clinical program is focused on
evaluating the lead epigenetic candidate apabetalone for the
treatment of cardiovascular disease and associated comorbidities,
and COVID-19.
Resverlogix common shares trade on the Toronto
Stock Exchange (TSX:RVX).
Follow us:
- Twitter: @Resverlogix_RVX
- LinkedIn:
https://www.linkedin.com/company/resverlogix-corp-/
For further information please contact:
Investor RelationsEmail: ir@resverlogix.comPhone:
403-254-9252
www.resverlogix.com
Resverlogix (TSX:RVX)
Historical Stock Chart
From Oct 2024 to Oct 2024
Resverlogix (TSX:RVX)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Resverlogix Corp (Toronto Stock Exchange): 0 recent articles
More News Articles